Ung/udg inhibition in brca-associated cancer
AssigneesInstitut Curie, Institut National de la Sante et de la Recherche Medicale
InventorsRaphaël CECCALDI, Yucel HATICE, Daniele MUSIANI
Life of this patent
Estimating the term…
Abstract
Methods and pharmaceutical compositions for the treatment of resistant HRD cancer, particularly resistant BRCA-associated cancer, chemo-resistant HRD cancer and chemo-resistant BRCA-associated cancer.
Claims12
A method of treating resistant Homologous Recombination Deficiency (HRD) cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a Uracil DNA glycosylase (UNG) inhibitor, wherein the UNG inhibitor is a molecule capable of silencing the gene expressing the UNG enzyme or a molecule inhibiting UNG enzymatic properties.
A method of treating resistant Homologous Recombination Deficiency (HRD) cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a Uracil DNA glycosylase (UNG) inhibitor and a pharmaceutical acceptable carrier, wherein the UNG inhibitor is a molecule capable of silencing the gene expressing the UNG enzyme or a molecule inhibiting UNG enzymatic properties.
A pharmaceutical composition comprising a Uracil DNA glycosylase (UNG) inhibitor in combination with a PARP inhibitor and a pharmaceutical acceptable carrier.
(canceled)
Dependencies are inferred from the claim text.